Jennifer Pogoriler

Jennifer Pogoriler

Auto-generated profile, based on publicly available information

Jennifer Pogoriler

Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NKNathan M. Kendsersky
Nathan M. Kendsersky
JLJarrett Lindsay
Jarrett Lindsay
EKE. Anders Kolb
E. Anders Kolb
MSMalcolm A. Smith
Malcolm A. Smith
BTBeverly A. Teicher
Beverly A. Teicher
JMJohn M. Maris
John M. Maris
Purpose: Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 is an immune checkpoint protein encoded by the CD276 gene that is overexpressed in many pediatric cancers. Here, we investigate the activity of the B7-H3–targeting antibody–drug conjugate (ADC) m276-SL-PBD in pediatric solid malignancy patient-derived (PDX) and cell line–derived xenograft (CDX) models. Experimental Design: B7-H3 expression was quantified by RNA sequencing and by IHC on pediatric PDX microarrays. We tested the safety and efficacy of m276-SL-PBD in two stages. Randomized trials of m276-SL-PBD of 0.5 mg/kg on days 1, 8, and 15 compared with vehicle were performed in PDX or CDX models of Ewing sarcoma (N = 3), rhabdomyosarcoma (N = 4), Wilms tumors (N = 2), osteosarcoma (N = 5), and neuroblastoma (N = 12). We then performed a single mouse trial in 47 PDX or CDX models using a single 0.5 m/kg dose of m276-SL-PBD. Results: The vast majority of PDX and CDX samples studied showed intense membranous B7-H3 expression (median H-score 177, SD 52). In the randomized trials, m276-SL-PBD showed a 92.3% response rate, with 61.5% of models showing a maintained complete response (MCR). These data were confirmed in the single mouse trial with an overall response rate of 91.5% and MCR rate of 64.4%. Treatment-related mortality rate was 5.5% with late weight loss observed in a subset of models dosed once a week for 3 weeks. Conclusions: m276-SL-PBD has significant antitumor activity across a broad panel of pediatric solid tumor PDX models.

1 July 2022 in RadioGraphics
Verified
Journal Article
Closed access
JNJie C. Nguyen
Jie C. Nguyen
SBSoroush Baghdadi
Soroush Baghdadi
JPJennifer Pogoriler
Jennifer Pogoriler
AGAndressa Guariento
Andressa Guariento
CRChamith S. Rajapakse
Chamith S. Rajapakse
AAAlexandre Arkader
Alexandre Arkader
A solid understanding of the role of imaging and the surgical options in the setting of pediatric osteosarcoma can have a direct and positive effect on the care of affected patients. Osteosarcoma is the most common primary bone sarcoma in children. Imaging plays a pivotal role in diagnostic workup, surgical planning, and follow-up monitoring for possible disease relapse. Surviv...

25 August 2022 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
JRJulia E. Rood
Julia E. Rood
ARAyman Rezk
Ayman Rezk
JPJennifer Pogoriler
Jennifer Pogoriler
LFLaura S. Finn
Laura S. Finn
JBJon M. Burnham
Jon M. Burnham
SCScott W. Canna
Scott W. Canna

7 July 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
NNNya D. Nelson
Nya D. Nelson
FXFeng Xu
Feng Xu
PCPrashant Chandrasekaran
Prashant Chandrasekaran
LLLeslie A. Litzky
Leslie A. Litzky
WPWilliam H. Peranteau
William H. Peranteau
JPJennifer Pogoriler
Jennifer Pogoriler

17 November 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
MMMehran Makvandi
Mehran Makvandi
MSMinu Samanta
Minu Samanta
PMPaul Martorano
Paul Martorano
HLHwan Lee
Hwan Lee
SGSarah B. Gitto
Sarah B. Gitto
JMJohn M. Maris
John M. Maris
Astatine-211-parthanatine ([211At]PTT) is an alpha-emitting radiopharmaceutical therapeutic that targets poly(adenosine-diphosphate-ribose) polymerase 1 (PARP1) in cancer cells. High-risk neuroblastomas exhibit among the highest PARP1 expression across solid tumors. In this study, we evaluated the efficacy of [211At]PTT using 11 patient-derived xenograft (PDX) mouse models of high-risk neuroblastoma, and assessed hematological and marrow toxicity in a CB57/BL6 healthy mouse model. We observed broad efficacy in PDX models treated with [211At]PTT at the maximum tolerated dose (MTD 36 MBq/kg/fraction x4) administered as a fractionated regimen. For the MTD, complete tumor response was observed in 81.8% (18 of 22) of tumors and the median event free survival was 72 days with 30% (6/20) of mice showing no measurable tumor >95 days. Reversible hematological and marrow toxicity was observed 72 hours post-treatment at the MTD, however full recovery was evident by 4 weeks post-therapy. These data support clinical development of [211At]PTT for high-risk neuroblastoma.

28 April 2020 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
NNNya D. Nelson
Nya D. Nelson
LLLeslie A. Litzky
Leslie A. Litzky
WPWilliam H. Peranteau
William H. Peranteau
JPJennifer Pogoriler
Jennifer Pogoriler
Congenital pulmonary airway malformations (CPAMs) are abnormalities of the lung arising during development. At our institution the majority of type I infantile CPAMs contain mucinous cell clusters (MCCs). The overlapping histology of MCCs and adult in situ mucinous adenocarcinomas, as well as reports of metastatic mucinous adenocarcinoma arising in CPAMs resected later in childhood raise concerns about the malignant potential of these cells. However, after adequate surgical resection, malignant recurrence has not been reported in infants with CPAMs. Despite benign behavior, MCCs often have histologic features that, in an adult, would be consistent with a diagnosis of adenocarcinoma. Therefore, to assess the spectrum of features that may be seen in these presumed precursor lesions, we characterized the histology of 671 MCCs spread across 44 infantile CPAMs and compared them to 10 adult mucinous adenocarcinomas. MCCs in CPAMS were often numerous, widespread, and located outside of the large cysts. Mucinous and nonmucinous epithelium within CPAMs showed complex architecture, making application of adult adenocarcinoma architectural patterns difficult. The MCCs within CPAMs displayed nuclear features similar to adult mucinous adenocarcinomas. The proliferative index in infantile MCCs was higher than in adult mucinous adenocarcinomas but was also higher in uninvolved infantile lung tissue. This work illustrates that histologic features typically associated with adenocarcinoma frequently occur within CPAMs; however, this does not alter their benign behavior. Therefore, extreme caution should be used if adult lung cancer terminology is applied to avoid significant potential psychological and physical harms associated with the label of adenocarcinoma.